2841. A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate (TZD) and Linezolid (LZD) for Treatment of Ventilated Gram-Positive (G+) Nosocomial Pneumonia
Richard G. Wunderink(Northwestern University), Carisa S De Anda(Merck & Co., Inc., Rahway, NJ, USA (United States)), Martin A. Croce(University of Tennessee Health Science Center), Joan R. Butterton(Merck & Co., Inc., Rahway, NJ, USA (United States)), Myra W. Popejoy(Merck & Co., Inc., Rahway, NJ, USA (United States)), Natasha Broyde(Merck & Co., Inc., Rahway, NJ, USA (United States)), Antoine Roquilly(Nantes Université), Daniel González(University of North Carolina at Chapel Hill), Jason Y. Kim(Children's Hospital of Philadelphia), Satoshi Fujimi(Osaka Prefectural Medical Center)
Cited by 2
Related Papers
Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults
|New England Journal of Medicine|2015|3.4k
Community-Acquired Pneumonia Requiring Hospitalization among U.S. Children
|New England Journal of Medicine|2015|1.9k
International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia
|European Respiratory Journal|2017|1.4k
Results of the CONTROL Trial: Efficacy and Safety of Recombinant Activated Factor VII in the Management of Refractory Traumatic Hemorrhage
|The Journal of Trauma: Injury, Infection, and Critical Care|2010|347